DISA has announced that a subsidiary of the company, Digital Life Line, has signed a tri-party licensing agreement with the National University of Singapore (NUS) and Singapore Health Services (SingHealth) on Dec 8 for the use of their new saliva-based Covid-19 antigen rapid test (ART) technology. 

This technology was co-developed by SingHealth Duke-NUS Academic Medical Centre and the NUS. Dubbed the Parallel Amplified Saliva rapid POint-of-caRe Test (PASPORT), the technology produces results in minutes, without the need for additional equipment or specially-trained personnel. 

In view of the ongoing Covid-19 pandemic, Digital Life Line plans to commercialise the new saliva-based ART kits, subject to Digital Life Line’s ability to obtain approval from the relevant regulatory authority.

To continue reading,

Sign in to access this Premium article.

Subscription entitlements:

Less than $9 per month
3 Simultaneous logins across all devices
Unlimited access to latest and premium articles
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)

Related Stories

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook